Under 10% of individuals who could benefit from obesity jabs including Wegovy are able to get them, caution the WHO as it issues its initial recommendations on the medications.
With in excess of 1,000,000,000 people worldwide currently living with obesity, it is urging broader and more equitable access to GLP-1 medication.
Based on forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 without intervention.
"Our new guidelines acknowledges that obesity is a long-term condition that can be addressed with holistic and ongoing treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and distribution challenges are significant obstacles to widespread access to the jabs that can help people shift considerable body mass, says the body.
Skinny Jab Shortage
Despite the present most favorable case, the manufacturing of these medications could only cover approximately 100 million people – less than 10% of the global need, per the health organization.
The advice calls on countries and companies to expand availability, by approaches including patent sharing.
A patent on semaglutide – the core ingredient of the drug Wegovy – is due to expire in multiple nations in 2026.
The Way Obesity Drugs Work
GLP-1 drugs replicate a natural hormone to delay gastric emptying, reduce hunger and enhance feelings of fullness so users consume fewer calories.
Patients commonly start to lose weight in the initial weeks of beginning the regular doses.
Studies suggests users may regain a significant portion within a year of discontinuing the medication, as their typical appetite come back.
To be above a healthy weight raises your chance for contracting medical conditions, like type 2 diabetes, heart disease, brain attack, and specific cancers.
Excess weight affects individuals in all nations and was linked to 3.7 million fatalities worldwide in 2024, per the health agency.
